Eli Lilly's Omvoh Surpasses J&J's Stelara in Crohn's Disease Phase III Trial

Eli Lilly's Omvoh has demonstrated superior long-term outcomes compared to Johnson & Johnson's Stelara in the treatment of Crohn's disease, as shown in the Phase III VIVID-1 trial. At the 52-week mark, Omvoh exhibited a nominally statistically significant better histologic response, including among patients with previous biologic treatment failures, according to ECCO mucosal histopathology criteria[1][2]. Omvoh’s mechanism involves selectively targeting the IL-23 cytokine, which plays a crucial role in reducing mucosal inflammation[1]. These results support Eli Lilly's regulatory submissions to expand Omvoh's label, potentially strengthening its market position amidst the growing competition from Stelara biosimilars[1][2].